A study conducted by pharmaceutical firm Pfizer has shown the new coronavirus variants first identified in the UK and South Africa only had a minor impact on the effectiveness of its vaccine.

The preliminary research, published online on 27 January, showed the antibodies developed by the vaccine were only slightly less effective against the South African variant’s mutations. Meanwhile, the antibodies were slightly better at binding to mutations found in the UK variant.